Sight Diagnostics

Funds

CK Hutchison-backed VC Longliv supports artificial intelligence-dependent blood testing with latest investment

Together with other investors such as Koch Disruptive Technologies based in the US and Israel-headquartered OurCrowd, Longliv is investing US$71 million ($97.5 million) in the company.
×